GLP-2 (T)
FDA ApprovedStrong EvidenceTirzepatide — GLP-1/GIP Dual Agonist
Vendor shorthand for Tirzepatide — FDA-approved dual GLP-1/GIP agonist achieving ~22% weight reduction.
Half-Life
~5 days
Molecular Weight
4813.5 g/mol
GLP-2 (T) is a vendor shorthand for Tirzepatide, where 'T' refers to Tirzepatide. FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management). The SURMOUNT-1 trial showed ~22.5% mean body weight reduction at 72 weeks — the highest pharmacological weight loss efficacy ever recorded. Tirzepatide is a dual GLP-1/GIP agonist; the 'GLP-2' in the vendor designation is a shorthand code, not a reference to biological GLP-2 hormone. See Tirzepatide profile for full details.
Also Known As
Amino Acid Sequence
Modified GLP-1/GIP hybrid with C20 fatty diacid
Reconstitution
See Tirzepatide profile. FDA-approved versions are pre-filled pens.
Open Reconstitution Calculator →